This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, H. Y. Articles by Kotchen, T. A. Search for Related Content PubMed PubMed Citation Articles by Zhang, H. Y. Articles by Kotchen, T. A.

Hypertension, Vol 24, 106-110, Copyright © 1994 by American Heart Association

ARTICLES

Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity

HY Zhang, SR Reddy and TA Kotchen
Department of Medicine, Medical College of Wisconsin, Milwaukee 53226.

Hypertension is often associated with insulin resistance, and several chemically diverse agents that increase insulin sensitivity attenuate the development of experimental hypertension. We undertook the present study to determine whether attenuation of hypertension by pioglitazone, a thiazolidinedione derivative that increases insulin sensitivity without increasing insulin secretion, is specifically related to its effect on insulin-mediated glucose uptake. Pioglitazone administered daily by oral gavage (20 mg/kg per day) for 3 weeks attenuated the development of hypertension in both the Dahl salt-sensitive (DS) rat (an insulin-resistant model of hypertension) and the one-kidney, one clip rat (a model of hypertension not associated with insulin resistance). Based on euglycemic insulin clamp studies in conscious animals, the glucose clearance rate was increased (P < .05) in pioglitazone-treated DS rats (36 +/- 3 mg/kg per minute) compared with control DS rats (27 +/- 1 mg/kg per minute). However, pioglitazone did not affect the glucose clearance rate in one-kidney, one clip hypertensive rats. Metformin, an unrelated agent that also improves glucose tolerance, had no significant effect on blood pressure or glucose clearance rate in either DS or one-kidney, one clip rats. Thus, the hypotensive effect of pioglitazone is not invariably associated with its capacity to improve insulin-induced glucose utilization.

This article has been cited by other articles:

				X. Ruan, F. Zheng, and Y. Guan PPARs and the kidney in metabolic syndrome Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1032 - F1047. [Abstract] [Full Text] [PDF]

				C. W Bolten, M. A Payne, W. G McDonald, P. M Blanner, R. C Chott, S. Ghosh, G. B Arhancet, N. R Staten, E. A Gulve, P. M Sullivan, et al. Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat Diabetes and Vascular Disease Research, June 1, 2007; 4(2): 117 - 123. [Abstract] [PDF]

				A. Zanchi, C. Perregaux, M. Maillard, D. Cefai, J. Nussberger, and M. Burnier The PPAR{gamma} agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1228 - E1234. [Abstract] [Full Text] [PDF]

				C. B Patle, J. A De Lemos, K. L Wyne, and D. K McGuire Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR{gamma} agonism Diabetes and Vascular Disease Research, September 1, 2006; 3(2): 65 - 71. [Abstract] [PDF]

				Y. Guan Peroxisome Proliferator-Activated Receptor Family and Its Relationship to Renal Complications of the Metabolic Syndrome J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2801 - 2815. [Abstract] [Full Text] [PDF]

				S. Y. Honisett, L. Stojanovska, K. Sudhir, B. A. Kingwell, T. Dawood, and P. A. Komesaroff Hormone Therapy Impairs Endothelial Function in Postmenopausal Women with Type 2 Diabetes Mellitus Treated with Rosiglitazone J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4615 - 4619. [Abstract] [Full Text] [PDF]

				M. J. Ryan, S. P. Didion, S. Mathur, F. M. Faraci, and C. D. Sigmund PPAR{gamma} Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic Mice Hypertension, March 1, 2004; 43(3): 661 - 666. [Abstract] [Full Text] [PDF]

				A. W. Cowley Jr, R. J. Roman, and H. J. Jacob Application of chromosomal substitution techniques in gene-function discovery J. Physiol., January 1, 2004; 554(1): 46 - 55. [Abstract] [Full Text] [PDF]

				C. Severino, P. Brizzi, A. Solinas, G. Secchi, M. Maioli, and G. Tonolo Low-dose dexamethasone in the rat: a model to study insulin resistance Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E367 - E373. [Abstract] [Full Text] [PDF]

				T. Ogihara, T. Asano, K. Ando, Y. Chiba, N. Sekine, H. Sakoda, M. Anai, Y. Onishi, M. Fujishiro, H. Ono, et al. Insulin Resistance With Enhanced Insulin Signaling in High-Salt Diet-Fed Rats Diabetes, March 1, 2001; 50(3): 573 - 583. [Abstract] [Full Text]

				M. Santure, M. Pitre, N. Gaudreault, A. Marette, A. Nadeau, and H. Bachelard Effect of metformin on the vascular and glucose metabolic actions of insulin in hypertensive rats Am J Physiol Gastrointest Liver Physiol, May 1, 2000; 278(5): G682 - G692. [Abstract] [Full Text] [PDF]

				T. Force and J. V. Bonventre Growth Factors and Mitogen-Activated Protein Kinases Hypertension, January 1, 1998; 31(1): 152 - 161. [Abstract] [Full Text] [PDF]

				M. S. Muntzel, A. Abe, and J. S. Petersen Effects of Adrenergic, Cholinergic and Ganglionic Blockade on Acute Depressor Responses to Metformin in Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 618 - 623. [Abstract] [Full Text]

				T. A. Kotchen Attenuation of Hypertension by Insulin-Sensitizing Agents Hypertension, August 1, 1996; 28(2): 219 - 223. [Full Text]